SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-080081
Filing Date
2022-03-21
Accepted
2022-03-21 08:11:02
Documents
15
Period of Report
2022-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d258593d8k.htm   iXBRL 8-K 34930
2 EX-10.1 d258593dex101.htm EX-10.1 50925
3 EX-99.1 d258593dex991.htm EX-99.1 77578
7 GRAPHIC g258593g0319073839036.jpg GRAPHIC 3088
  Complete submission text file 0001193125-22-080081.txt   321181

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA urgn-20220317.xsd EX-101.SCH 2854
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20220317_lab.xml EX-101.LAB 17350
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20220317_pre.xml EX-101.PRE 10850
9 EXTRACTED XBRL INSTANCE DOCUMENT d258593d8k_htm.xml XML 3264
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 22754260
SIC: 2834 Pharmaceutical Preparations